SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a broad crypto selloff linked to the reported record-scale Binance hack, which has stirred concerns about exchange security and possible further selling. Traders are divided between viewing the dip as a buying opportunity and warning that trust concerns and market weakness could bring more downside.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming earnings report is the main focus, with traders debating whether strong results and raised guidance can overcome a high bar set by its valuation. Bulls point to AI demand and growth, while bears warn that a routine beat may not be enough amid a broader repricing of AI stocks.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA accelerated approval of Inovios competing RRP treatment has raised concerns about competition for Precigens PAPZIMEOS. Traders debate whether the rivals potential to reduce surgeries will erode PAPZIMEOS uptake or whether Precigens first-mover lead, full approval, and established commercial presence will help it retain an advantage.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORUs sharp decline is drawing attention as South Korean stocks, particularly semiconductor shares, sell off amid concerns about AI demand and chip competition. Traders are divided between buying what they see as an oversold dip and warning that further losses and leverage-driven volatility could deepen the drop.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of Marvells possible acquisition of Lumentum are driving attention, with traders focused on potential financing, shareholder dilution, and execution risks. Some see the deal as a strategic way to secure optical components for AI data centers, while others view the selloff as justified or an opportunity to buy the dip; the talks remain unconfirmed.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders viewing the report as evidence of improving performance. The community is debating whether the pullback reflects profit-taking and broader market weakness or whether heavy short interest could fuel further gains; squeeze claims remain speculation.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Mercks stronger-than-expected third-quarter results and raised full-year outlook are drawing attention, with traders also highlighting a bullish flag pattern and a potential breakout. Some discussion continues around the melanoma cancer-vaccine partnership with Moderna, but views differ on how much commercial value the trial results may add.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

ANET is drawing attention after a sharp pullback from recent highs, with traders pointing to selling pressure and technical weakness ahead of the next earnings report; some also cite bearish options flow and insider sales, though these are not established as the cause. The community is split between treating the decline as a buying opportunity based on Aristas AI data-center networking demand and cash-rich balance sheet, and waiting for further downside or support to form.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharply weaker-than-expected outlook after its quarterly reportamid soft PC demand and supply constraintstriggered a historic selloff and renewed concerns about its recovery and exposure to the AI trade. Traders are split between calling the drop an overreaction and buying the dip, and warning that further losses may follow.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is selling off alongside the semiconductor and AI trade as investors question whether hyperscalers enormous AI spending can generate adequate returns, with concerns about financing structures and circular spending adding to pressure. Traders disagree on whether this signals trouble for chip demand or is a sector-wide repricing that overlooks Broadcoms role as a supplier benefiting from that spending.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics to Report Third Quarter 2026 Financial Results

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report third quarter 2026 financial results on Monday, November 2, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general...

Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI (sparsentan) May Modify Underlying Disease Pathophysiology in IgA Nephropathy

Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI (sparsentan) may modify the underlying disease pathophysiology in people with IgA nephropathy (IgAN). Data were shared today in an oral presentation at the...

AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA Nephropathy

AZN wins accelerated FDA approval for Ultomiris in IgA nephropathy, marking the fifth approved indication for the drug in the United States.

Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to Decline

Travere (TVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 178,580 shares of its common stock to 33 new employees, consisting of inducement stock options to...

Travere to Present New Data Supporting FILSPARI (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI...

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Travere Therapeutics, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 30, 2026NEW YORK, Sept. 30, 2026/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI (sparsentan) in Focal Segmental Glomerulosclerosis

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders, directed to certain...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright analysts said the early data and the drug’s overall profile are “pointing in the right direction.”</li><li>Civorebrutinib has the potential to become “a best-in-class” treatment in its category, it added.</li><li>Travere will pay Everest Medicines $112.5 million upfront.</li></ul>Shares of Travere Therapeutics (TVTX) fell as much as 6% on Tuesday but recovered some of the losses after H.C. Wainwright raised its price target on the stock to $67 from $57 and kept a ‘Buy’ rating, an upgrade that followed the company’s announcement expanding its lineup of rare-kidney-disease treatments by licensing a promising new drug. &nbsp;The fresh price target implies a potential upside of about 49% from the stock’s last close.<h2 class="st-heading-2">TVTX’s Licensing Deal</h2>The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States and all other markets outside China and certain countries in East and Southeast Asia. Civorebrutinib is an oral pill still in early testing that is designed to calm overactive parts of the immune system that can damage the kidneys in rare diseases. These conditions include primary membranous nephropathy, focal segmental glomerulosclerosis, and minimal change disease—illnesses that currently have limited treatment options and leave many patients with few good choices.Early results from a small clinical study in patients with one of these kidney conditions were encouraging. The drug quickly lowered harmful antibodies and excess protein in the urine, helped more patients reach remission, and kept kidney function stable for up to a year, with few side effects reported so far. H.C. Wainwright analysts said the early data and the drug’s overall profile are “pointing in the right direction” and that civorebrutinib has the potential to become “a best-in-class” treatment in its category.Travere will pay Everest Medicines $112.5 million upfront. If the drug succeeds in later testing and reaches the market, Travere could pay up to about $1.03 billion in additional milestone payments, plus ongoing royalties on sales ranging from the high single digits to low double digits.Travere plans to study civorebrutinib next in patients with primary membranous nephropathy and certain forms of focal segmental glomerulosclerosis and minimal change disease, with the possibility of testing it in other related conditions later. The agreement is still subject to standard regulatory approvals, including antitrust clearance.How Did Retail Traders React?On Stocktwits, retail sentiment around TVTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.A Stocktwits user said that they are skeptical of the licensing deal until they see more data.<stembedurl>https://www.stocktwits.com/JFais/message/655087843</stembedurl>Another cheered the deal as “big news.”<stembedurl>https://www.stocktwits.com/buckyebullrider01/message/655078299</stembedurl><a href="https://stocktwits.com/symbol/TVTX">TVTX stock</a> has gained about 177% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/paramount-skydance-advances-110-billion-warner-bros-deal-reportedly-seeks-eu-approval/cZ0030AReDd">Paramount Skydance Advances $110B Warner Bros. Deal, Reportedly Seeks EU Approval</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Travere Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The licensing deal, announced Tuesday with China’s Everest Medicines, gives Travere exclusive rights to develop and sell the drug civorebrutinib in the United States.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$50.39
Prev Close	$50.57
Open	$50.01
Dividend Yield	0.00%
50-Day Moving Average	$59.06
Beta	1.32
Avg. Volume	1.54M
PE Ratio	-65.98

52-Week High	$68.73
52-Week Low	$22.59
Market Capitalization	$4.75B
EPS (Annual)	-$0.5634
Price to Book	193.52
Revenue Per Employee	$987,380.28

Feed

News

Sentiment

Earnings

Fundamentals

Info

TVTX Fundamentals